Oncotelic Therapeutics Inc. (OTCQB: OTLC) is making strides in pharmaceutical innovation by leveraging ultra-small carrier technologies to improve existing cancer treatments. The company's focus on nanoparticle drug delivery aims to enhance bioavailability, precision targeting, and therapeutic performance of anticancer compounds. This approach is seen as potentially transformative, akin to the impact of monoclonal antibodies on biologics.
According to a recent article, Oncotelic is advancing nanoparticle-based delivery through its joint venture entity, utilizing the Deciparticle platform. The company is preparing for its first-in-human study of an intravenous Everolimus (Afinitor) nanoformulation, known as Sapu-003, developed with its subsidiary Sapu Nano. This formulation is designed to overcome the absorption and tumor-penetration limitations of oral Everolimus by delivering full bioavailability via intravenous nanoparticle delivery. For more details, the full article can be accessed at https://ibn.fm/VaID8.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company dedicated to oncology and immunotherapy products, targeting high-unmet-need cancers and rare pediatric indications. The company's pipeline includes innovative late-stage therapeutic candidates. Under the leadership of CEO Dr. Vuong Trieu, who holds over 150 patent applications and 39 issued U.S. patents, Oncotelic also licenses and co-develops drug candidates through joint ventures. For instance, the company owns 45% of GMP Bio, a joint venture advancing its own pipeline that complements Oncotelic's strategic position in oncology and rare disease therapeutics.
The implications of this announcement are significant. If successful, the Sapu-003 nanoformulation could revolutionize the delivery of Everolimus, a drug widely used for certain cancers but limited by oral absorption issues. Enhanced bioavailability and tumor penetration could lead to better patient outcomes, reduced side effects, and expanded therapeutic applications. Moreover, Oncotelic's advancements in nanoparticle technology may pave the way for similar improvements in other cancer therapies, potentially transforming treatment paradigms.
Investors and stakeholders can find the latest news and updates on OTLC in the company's newsroom at https://ibn.fm/OTLC.
